On October 7, 2019 Veracyte, Inc. (Nasdaq: VCYT) reported that preliminary clinical data for the company’s noninvasive nasal swab test – the first of its kind – for early detection of lung cancer will be presented at the annual meeting of the American College of Chest Physicians (CHEST), being held October 18-23 in New Orleans (Press release, Veracyte, OCT 7, 2019, View Source [SID1234540087]). The presentation will highlight the early performance characteristics and intended use of the novel genomic test.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Additionally, data from five studies demonstrating the clinical performance and utility of Veracyte’s Percepta Genomic Sequencing Classifier (GSC) and Envisia Genomic Classifier – which are used to improve the diagnosis of lung cancer and idiopathic pulmonary fibrosis (IPF), respectively – will be presented during the CHEST meeting.
"We look forward to the CHEST meeting, where data from multiple studies will demonstrate our genomic tests’ ability to answer important clinical questions that inform diagnosis and treatment decisions for patients with suspected cancer or other diseases," said Bonnie Anderson, Veracyte’s chairman and chief executive officer. "This includes five studies reinforcing the value that our Percepta and Envisia genomic classifiers provide to patients with potential lung cancer and interstitial lung diseases, including IPF. We are particularly excited to share new data that demonstrate significant progress in our development of the first noninvasive nasal swab test for early lung cancer detection."
Following are details regarding the nasal swab test data presentation at CHEST:
Title:
Lung Cancer Detection via Whole-Transcriptome RNA Sequencing of Nasal Epithelium
Presenter:
Carla R. Lamb, M.D., Lahey Hospital & Medical Center
Date/Time:
Tuesday, October 22, 1:00-2:00 p.m. CT
Location:
Ernest N. Morial Convention Center, Exhibit Hall – Poster Area 1
Abstract #:
4224
Following are details regarding the clinical utility data presentations for the Envisia Genomic Classifier:
Title:
Evaluating Clinical Utility of a UIP Genomic Classifier in Subjects With and Without a HRCT Pattern of UIP
Presenter:
Jonathan H. Chung, M.D., The University of Chicago Medicine
Date/Time:
Sunday, October 20, 2:30-2:45 p.m. CT
Location:
Ernest N. Morial Convention Center, Room 291
Abstract #:
4010 (oral presentation)
Title:
Combining Radiology and Envisia, a Molecular Classifier, to Improve Usual Interstitial Pneumonia (UIP) Diagnosis
Presenter:
Sadia Benzaquen, M.D., University of Cincinnati College of Medicine
Date/Time:
Monday, October 21, 1:45-2:00 p.m. CT
Location:
Ernest N. Morial Convention Center, Room 281
Abstract #:
4060 (oral presentation)
Title:
Employing Bronchoscopic Lung Cryobiopsy and a Genomic Classifier in the Multidisciplinary Diagnosis of Diffuse Interstitial Lung Diseases
Presenter:
Fayez Kheir, M.D., Tulane University School of Medicine
Date/Time:
Tuesday, October 22, 8:45-9:45 a.m. CT
Location:
Ernest N. Morial Convention Center, Room 288
Abstract #:
4805 (oral presentation)
Following are details for the clinical performance and utility data presentations for the Percepta classifier:
Title:
Improving Indeterminate Pulmonary Nodule Management with the Percepta Genomic Sequencing Classifier
Presenter:
Peter Mazzone, M.D., M.P.H., Cleveland Clinic
Date/Time:
Wednesday, October 23, 10:45-11:45 a.m. CT
Location:
Ernest N. Morial Convention Center, Room 298
Abstract #:
4815 (oral presentation)
Title:
Use of Percepta Genomic Classifier in Lung Nodule Management: A County Hospital Experience
Presenter:
Waasil Kareem, M.D., Keck School of Medicine of the University of Southern California
Date/Time:
Wednesday, October 23, 9:45-10:45 a.m. CT
Location:
Ernest N. Morial Convention Center, Exhibit Hall – Poster Area 4
Abstract #:
4232 (poster presentation)